(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Fundamental Home Exercise center Hardware: Amplify Your Exercises - 2PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- 3Vote in favor of the pasta that makes good dieting charming!
- 4Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 5Extraordinary Shows to Long distance race on a Plane
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- Wonderful Sea shores All over the Planet
- Best Streaming Gadget for Your Home Theater
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- Which Aircraft Do You Suggest? Vote
- Manual for Big name Work out schedules
- Vote in favor of your #1 sort of juice
- 2024's Savvy Home Gadgets for an Associated Way of life
